Keloid- Pipeline Insight, 2025
Description
DelveInsight’s, “Keloid- Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Keloid pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Keloid: Overview
Keloids are a type of hypertrophic scar that extends beyond the boundaries of the initial skin injury, forming a raised and often irregularly shaped growth. Unlike typical scars, keloids do not regress over time and can continue to expand, sometimes causing physical and cosmetic discomfort. They most commonly occur following skin trauma such as surgical incisions, burns, severe acne, or even minor scratches. Individuals with darker skin tones, such as those of African, Hispanic, and Asian descent, as well as those with a family history of keloids, are more prone to developing these scars. Keloids are characterized by their raised and shiny appearance, often taking on a color that ranges from pink to red to dark brown, depending on the person's skin tone. They are typically firm or rubbery to the touch and can be significantly larger than the original wound. Common symptoms include itchiness, tenderness, and sometimes pain, particularly as the keloid grows. These symptoms can lead to discomfort and functional impairment, especially if the keloid forms over joints or other areas of frequent movement.
The exact cause of keloid formation is not fully understood, but it involves an overproduction of collagen during the wound healing process. Factors contributing to keloid formation include genetic predisposition, skin tension, and the severity of the initial injury. The pathophysiology of keloids involves an imbalance between the synthesis and degradation of collagen, leading to excessive scar tissue formation. This imbalance may be influenced by various cellular and molecular mechanisms, including inflammatory responses and fibroblast activity.
Diagnosis of keloids is primarily clinical, based on the characteristic appearance and history of the lesion. Physicians may conduct a physical examination and review the patient's medical history to identify any contributing factors. In some cases, a skin biopsy may be performed to rule out other conditions such as hypertrophic scars or skin tumors. However, the distinct appearance of keloids usually makes this step unnecessary.
Treatment options for keloids aim to reduce their size, alleviate symptoms, and prevent recurrence. Corticosteroid injections are commonly used to flatten keloids and reduce inflammation. Surgical removal is another option, though it is often combined with other treatments like corticosteroids or radiation therapy to minimize the risk of recurrence. Laser therapy can reduce the size and improve the color of keloids, while cryotherapy involves freezing the keloid to diminish its size. Silicone sheets and gels, applied regularly, can help flatten keloids and reduce redness. In severe cases, pressure therapy or radiation therapy may be employed. Preventive measures include proper wound care, avoiding unnecessary skin trauma, and using silicone gel or sheets early in the wound healing process.
""Keloid- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Keloid pipeline landscape is provided which includes the disease overview and Keloid treatment guidelines. The assessment part of the report embraces, in depth Keloid commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Keloid collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Keloid report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Keloid Emerging Drugs
Further product details are provided in the report……..
Keloid: Therapeutic Assessment
This segment of the report provides insights about the different Keloid drugs segregated based on following parameters that define the scope of the report, such as:
Keloid: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Keloid therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Keloid drugs.
Keloid Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Keloid: Overview
Keloids are a type of hypertrophic scar that extends beyond the boundaries of the initial skin injury, forming a raised and often irregularly shaped growth. Unlike typical scars, keloids do not regress over time and can continue to expand, sometimes causing physical and cosmetic discomfort. They most commonly occur following skin trauma such as surgical incisions, burns, severe acne, or even minor scratches. Individuals with darker skin tones, such as those of African, Hispanic, and Asian descent, as well as those with a family history of keloids, are more prone to developing these scars. Keloids are characterized by their raised and shiny appearance, often taking on a color that ranges from pink to red to dark brown, depending on the person's skin tone. They are typically firm or rubbery to the touch and can be significantly larger than the original wound. Common symptoms include itchiness, tenderness, and sometimes pain, particularly as the keloid grows. These symptoms can lead to discomfort and functional impairment, especially if the keloid forms over joints or other areas of frequent movement.
The exact cause of keloid formation is not fully understood, but it involves an overproduction of collagen during the wound healing process. Factors contributing to keloid formation include genetic predisposition, skin tension, and the severity of the initial injury. The pathophysiology of keloids involves an imbalance between the synthesis and degradation of collagen, leading to excessive scar tissue formation. This imbalance may be influenced by various cellular and molecular mechanisms, including inflammatory responses and fibroblast activity.
Diagnosis of keloids is primarily clinical, based on the characteristic appearance and history of the lesion. Physicians may conduct a physical examination and review the patient's medical history to identify any contributing factors. In some cases, a skin biopsy may be performed to rule out other conditions such as hypertrophic scars or skin tumors. However, the distinct appearance of keloids usually makes this step unnecessary.
Treatment options for keloids aim to reduce their size, alleviate symptoms, and prevent recurrence. Corticosteroid injections are commonly used to flatten keloids and reduce inflammation. Surgical removal is another option, though it is often combined with other treatments like corticosteroids or radiation therapy to minimize the risk of recurrence. Laser therapy can reduce the size and improve the color of keloids, while cryotherapy involves freezing the keloid to diminish its size. Silicone sheets and gels, applied regularly, can help flatten keloids and reduce redness. In severe cases, pressure therapy or radiation therapy may be employed. Preventive measures include proper wound care, avoiding unnecessary skin trauma, and using silicone gel or sheets early in the wound healing process.
""Keloid- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Keloid pipeline landscape is provided which includes the disease overview and Keloid treatment guidelines. The assessment part of the report embraces, in depth Keloid commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Keloid collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Keloid R&D. The therapies under development are focused on novel approaches to treat/improve Keloid.
This segment of the Keloid report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Keloid Emerging Drugs
- STP705: Sirnaomics, Inc.
Further product details are provided in the report……..
Keloid: Therapeutic Assessment
This segment of the report provides insights about the different Keloid drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Keloid
- There are approx. 5+ key companies which are developing the therapies for Keloid. The companies which have their Keloid drug candidates in the most advanced stage, i.e. phase II include, Sirnaomics, Inc.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Keloid: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Keloid therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Keloid drugs.
Keloid Report Insights
- Keloid Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Keloid drugs?
- How many Keloid drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Keloid?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Keloid therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Keloid and their status?
- What are the key designations that have been granted to the emerging drugs?
- Sirnaomics
- Yuhan Pharmaceuticals
- Lemonex Inc.,
- CellionBioMed
- STP705
- YHC1113
- LEM-S401
- CBM C1
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Keloid: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Keloid– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- STP705: Sirnaomics, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Keloid Key Companies
- Keloid Key Products
- Keloid- Unmet Needs
- Keloid- Market Drivers and Barriers
- Keloid- Future Perspectives and Conclusion
- Keloid Analyst Views
- Keloid Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
